טוען...
NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
Immunotherapy represents a promising new avenue for the treatment of multiple myeloma (MM) patients, particularly with the availability of Monoclonal Antibodies (mAbs) as anti-CD38 Daratumumab and Isatuximab and anti-SLAM-F7 Elotuzumab. Although a clear NK activation has been demonstrated for Elotuz...
שמור ב:
| הוצא לאור ב: | Cells |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7140687/ https://ncbi.nlm.nih.gov/pubmed/32245149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9030768 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|